← Back to Search

CD73 inhibitor

HLX23 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Shanghai Henlius Biotech

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through measured progressive disease (estimated at up to 2 years)

Awards & highlights

Study Summary

The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.

Eligible Conditions

Advanced Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through disease progression or death (estimated at up to 2 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through disease progression or death (estimated at up to 2 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through disease progression or death (estimated at up to 2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants with Dose Limiting Toxicity

Recommended phase 2 dose of HLX23

maximum tolerated dose of HLX23

Secondary outcome measures

Disease Control Rate (DCR)

Immunogenicity

Overall Response Rate (ORR)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: HLX23Experimental Treatment1 Intervention

HLX23 administered IV.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Shanghai Henlius BiotechLead Sponsor

87 Previous Clinical Trials

15,738 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare institutions in the U.S. are currently participating in this clinical experiment?

"This experiment is presently enlisting participants from 6 distinct sites, including those based in Fairway, LA and Orange City. To mitigate the burden of travel associated with taking part in this trial, it may be prudent to select the closest location available."

Answered by AI

Has Health and Human Services sanctioned HLX23 for use?

"As this is only a Phase 1 trial, with scant evidence of safety and efficacy, our team at Power has given HLX23 a score of 1 out of 3."

Answered by AI

What is the aggregate figure of study participants enrolled in this experiment?

"Affirmative. Clinicaltrials.gov reflects that this research endeavour, which was initially published on July 18th 2022, is actively recruiting participants. In total, 30 people need to be recruited from 6 distinct sites."

Answered by AI

What tangible results are anticipated from this trial?

"As per Shanghai Henlius Biotech, the primary aim of this trial – which will span 21 days - is to assess Dose Limiting Toxicity (DLT). Additionally, secondary outcomes such as Disease Control Rate (DCR), Pharmacodynamic(PD) and Overall Response Rate (ORR) shall undergo evaluation."

Answered by AI

Are there any participants being accepted into this research endeavor currently?

"Affirmative. Information on clinicaltrials.gov reveals that this medical study, which was initially posted on July 18th 2022, is actively seeking participants. Approximately 30 patients must be enrolled from 6 different research centres."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

2022. "A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04797468.